Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) has initiated its first clinical site in the U.S. for a phase 3 trial of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE